Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Beam Therapeutics (BEAM)

Beam Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BEAM
DateTimeSourceHeadlineSymbolCompany
13/01/202512:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
13/01/202512:00GlobeNewswire Inc.Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsNASDAQ:BEAMBeam Therapeutics Inc
06/01/202522:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
06/01/202522:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
03/01/202501:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/12/202400:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/12/202400:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
19/12/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
19/12/202421:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
17/12/202412:00GlobeNewswire Inc.Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
09/12/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
08/12/202418:45GlobeNewswire Inc.Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
07/12/202416:30GlobeNewswire Inc.Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
06/12/202412:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
06/12/202412:00GlobeNewswire Inc.Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerNASDAQ:BEAMBeam Therapeutics Inc
04/12/202412:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
04/12/202412:00GlobeNewswire Inc.Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderNASDAQ:BEAMBeam Therapeutics Inc
12/11/202421:01GlobeNewswire Inc.Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
08/11/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
05/11/202414:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
05/11/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
05/11/202414:00GlobeNewswire Inc.Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
05/11/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
05/11/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
05/11/202411:30GlobeNewswire Inc.Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNASDAQ:BEAMBeam Therapeutics Inc
29/10/202410:30GlobeNewswire Inc.Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
21/10/202420:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BEAMBeam Therapeutics Inc
16/10/202420:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
15/10/202415:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
07/10/202421:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BEAM